Market Overview:
Afatinib Dimaleate is a tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR) and ErbB2 receptors. Afatinib Dimaleate is used to treat certain types of cancer, including non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck. It is also used to treat people with EGFR mutations in their tumors. The market for Global Afatinib Dimaleate was xx million US$ in 2018 and is expected to xx million US$ by the end of 2030, growing at a CAGR of xx% between 2018 and 2030. The major drivers for this market are increasing incidence rates of NSCLC, rising prevalence of EGFR mutations, technological advancements in afatinib dimaleate therapy, increasing healthcare expenditure across the globe etc.
Product Definition:
Afatinib Dimaleate is a kinase inhibitor used to treat non-small cell lung cancer. It is a tyrosine kinase inhibitor that works by blocking the signals that promote cancer growth.
Global Afatinib Dimaleate Market Size Growth Rate by Drug Specifications: 2016 VS 2021 VS 2027:
Global Afatinib Dimaleate market was valued at USD 5.6 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.7% from 2021 to 2027. The increasing prevalence of cancer, such as gastrointestinal stromal tumors, bladder cancer, non-small cell lung cancer, and breast carcinoma among others is anticipated to drive the market over the forecast period.
20 mg:
20 mg is used to treat hereditary angioedema, which is a rare chronic condition that causes swelling of the skin and other body parts due to an immune-mediated mechanism. It affects less than one in a million people each year. The medicine works by decreasing the production of leukotrienes and prostaglandins, two types of chemicals that cause pain, inflammation, swelling & itching.
Application Insights:
The treatment of EGFR mutated non-small cell lung cancer held the largest share in 2016. This is attributed to the availability of a number of drugs for this type of cancer and increasing incidence rates. In addition, key market players are engaged in promoting awareness about the product benefits for treating this disease. For instance, Pfizer launched Plegridy & Daclizumab (P/D) tablets & Xeljanz (Xeljaba) injection for patients with unresectable or refractory EGFR-mutated NSCL doublets or solitary NSC tumor across various countries such as Germany, U.K., Japan and U.S.
Regional Analysis:
In 2017, Asia Pacific led the market with a share of over 60% and is anticipated to witness significant growth in the near future. This can be attributed toEGFR mutation being most prevalent in Asian countries such as India and China. In addition, increasing healthcare expenditure by governments as well as individuals coupled with rising awareness about cancer treatment options are some other factors responsible for regional growth.
The presence of key manufacturers such as Pfizer Inc., Merck & Co., Inc.; GlaxoSmithKline plc; Sanofi; Novartis AG; Bayer AG among others is also expected to drive the market during forecast period. The majority share held by Asia Pacific can be attributed to Japan which has one of the highest EGFR mutation prevalence rates globally along with other East Asian countries such as South Korea, Taiwan and Hong Kong SAR China (SAR).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the afatinib dimaleate market. According to a study by American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from the disease. This number is expected to rise in future due to increase in aging population and lifestyle changes.
- Rising demand for targeted therapies: The rising demand for targeted therapies is another major growth driver for afatinib dimaleate market as they offer better treatment outcomes as compared to traditional chemotherapy regimens. They are also associated with fewer side effects which has led to their increasing adoption across the globe.
Scope Of The Report
Report Attributes
Report Details
Report Title
Afatinib Dimaleate Market Research Report
By Type
Global Afatinib Dimaleate Market Size Growth Rate by Drug Specifications: 2016 VS 2021 VS 2027, 20 mg, 30 mg, 40 mg
By Application
Treatment of EGFR Mutated Non-Small Cell Lung Cancer, Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
By Companies
Boehringer Ingelheim Pharmaceuticals, APExBIO Technology LLC, Carbosynth Ltd, Biorbyt, Cayman Chemical Company, Target Molecule Corp., Frontier Specialty Chemicals, Combi-Blocks, Selleck Chemicals, AvaChem Scientific, Advanced ChemBlocks Inc, Glpbio, Nanjing Xize Pharmaceutical Technology Co., Ltd, Shandong Haiwo Biotechnology Co., Ltd, J&K Scientific, Shanghai McLin Biochemical Technology Co., Ltd, Beijing Sjar Technology Development Co., Ltd., Beijing Wokai Biotechnology Co., Ltd, Ningbo Zhenlei Chemical Co., Ltd., Beijing Mreda Technology Co., Ltd, MedBio Pharmaceutical Technology Inc, Shanghai Dibai Biotechnology Co., Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
224
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Afatinib Dimaleate Market Report Segments:
The global Afatinib Dimaleate market is segmented on the basis of:
Types
Global Afatinib Dimaleate Market Size Growth Rate by Drug Specifications: 2016 VS 2021 VS 2027, 20 mg, 30 mg, 40 mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Treatment of EGFR Mutated Non-Small Cell Lung Cancer, Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Boehringer Ingelheim Pharmaceuticals
- APExBIO Technology LLC
- Carbosynth Ltd
- Biorbyt
- Cayman Chemical Company
- Target Molecule Corp.
- Frontier Specialty Chemicals
- Combi-Blocks
- Selleck Chemicals
- AvaChem Scientific
- Advanced ChemBlocks Inc
- Glpbio
- Nanjing Xize Pharmaceutical Technology Co., Ltd
- Shandong Haiwo Biotechnology Co., Ltd
- J&K Scientific
- Shanghai McLin Biochemical Technology Co., Ltd
- Beijing Sjar Technology Development Co., Ltd.
- Beijing Wokai Biotechnology Co., Ltd
- Ningbo Zhenlei Chemical Co., Ltd.
- Beijing Mreda Technology Co., Ltd
- MedBio Pharmaceutical Technology Inc
- Shanghai Dibai Biotechnology Co., Ltd
Highlights of The Afatinib Dimaleate Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Global Afatinib Dimaleate Market Size Growth Rate by Drug Specifications: 2016 VS 2021 VS 2027
- 20 mg
- 30 mg
- 40 mg
- By Application:
- Treatment of EGFR Mutated Non-Small Cell Lung Cancer
- Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Afatinib Dimaleate Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Afatinib Dimaleate is a cancer drug that inhibits the growth of cancer cells. It is used to treat advanced or metastatic non-small cell lung cancer (NSCLC).
Some of the major companies in the afatinib dimaleate market are Boehringer Ingelheim Pharmaceuticals, APExBIO Technology LLC, Carbosynth Ltd, Biorbyt, Cayman Chemical Company, Target Molecule Corp., Frontier Specialty Chemicals, Combi-Blocks, Selleck Chemicals, AvaChem Scientific, Advanced ChemBlocks Inc, Glpbio, Nanjing Xize Pharmaceutical Technology Co., Ltd, Shandong Haiwo Biotechnology Co., Ltd, J&K Scientific, Shanghai McLin Biochemical Technology Co., Ltd, Beijing Sjar Technology Development Co., Ltd., Beijing Wokai Biotechnology Co., Ltd, Ningbo Zhenlei Chemical Co., Ltd., Beijing Mreda Technology Co., Ltd, MedBio Pharmaceutical Technology Inc, Shanghai Dibai Biotechnology Co., Ltd.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Afatinib Dimaleate Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Afatinib Dimaleate Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Afatinib Dimaleate Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Afatinib Dimaleate Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Afatinib Dimaleate Market Size & Forecast, 2018-2028
4.5.1 Afatinib Dimaleate Market Size and Y-o-Y Growth
4.5.2 Afatinib Dimaleate Market Absolute $ Opportunity
Chapter 5 Global Afatinib Dimaleate Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Afatinib Dimaleate Market Size Forecast by Type
5.2.1 Global Afatinib Dimaleate Market Size Growth Rate by Drug Specifications: 2016 VS 2021 VS 2027
5.2.2 20 mg
5.2.3 30 mg
5.2.4 40 mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Afatinib Dimaleate Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Afatinib Dimaleate Market Size Forecast by Applications
6.2.1 Treatment of EGFR Mutated Non-Small Cell Lung Cancer
6.2.2 Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Afatinib Dimaleate Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Afatinib Dimaleate Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Afatinib Dimaleate Analysis and Forecast
9.1 Introduction
9.2 North America Afatinib Dimaleate Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Afatinib Dimaleate Market Size Forecast by Type
9.6.1 Global Afatinib Dimaleate Market Size Growth Rate by Drug Specifications: 2016 VS 2021 VS 2027
9.6.2 20 mg
9.6.3 30 mg
9.6.4 40 mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Afatinib Dimaleate Market Size Forecast by Applications
9.10.1 Treatment of EGFR Mutated Non-Small Cell Lung Cancer
9.10.2 Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Afatinib Dimaleate Analysis and Forecast
10.1 Introduction
10.2 Europe Afatinib Dimaleate Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Afatinib Dimaleate Market Size Forecast by Type
10.6.1 Global Afatinib Dimaleate Market Size Growth Rate by Drug Specifications: 2016 VS 2021 VS 2027
10.6.2 20 mg
10.6.3 30 mg
10.6.4 40 mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Afatinib Dimaleate Market Size Forecast by Applications
10.10.1 Treatment of EGFR Mutated Non-Small Cell Lung Cancer
10.10.2 Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Afatinib Dimaleate Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Afatinib Dimaleate Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Afatinib Dimaleate Market Size Forecast by Type
11.6.1 Global Afatinib Dimaleate Market Size Growth Rate by Drug Specifications: 2016 VS 2021 VS 2027
11.6.2 20 mg
11.6.3 30 mg
11.6.4 40 mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Afatinib Dimaleate Market Size Forecast by Applications
11.10.1 Treatment of EGFR Mutated Non-Small Cell Lung Cancer
11.10.2 Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Afatinib Dimaleate Analysis and Forecast
12.1 Introduction
12.2 Latin America Afatinib Dimaleate Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Afatinib Dimaleate Market Size Forecast by Type
12.6.1 Global Afatinib Dimaleate Market Size Growth Rate by Drug Specifications: 2016 VS 2021 VS 2027
12.6.2 20 mg
12.6.3 30 mg
12.6.4 40 mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Afatinib Dimaleate Market Size Forecast by Applications
12.10.1 Treatment of EGFR Mutated Non-Small Cell Lung Cancer
12.10.2 Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Afatinib Dimaleate Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Afatinib Dimaleate Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Afatinib Dimaleate Market Size Forecast by Type
13.6.1 Global Afatinib Dimaleate Market Size Growth Rate by Drug Specifications: 2016 VS 2021 VS 2027
13.6.2 20 mg
13.6.3 30 mg
13.6.4 40 mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Afatinib Dimaleate Market Size Forecast by Applications
13.10.1 Treatment of EGFR Mutated Non-Small Cell Lung Cancer
13.10.2 Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Afatinib Dimaleate Market: Competitive Dashboard
14.2 Global Afatinib Dimaleate Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Boehringer Ingelheim Pharmaceuticals
14.3.2 APExBIO Technology LLC
14.3.3 Carbosynth Ltd
14.3.4 Biorbyt
14.3.5 Cayman Chemical Company
14.3.6 Target Molecule Corp.
14.3.7 Frontier Specialty Chemicals
14.3.8 Combi-Blocks
14.3.9 Selleck Chemicals
14.3.10 AvaChem Scientific
14.3.11 Advanced ChemBlocks Inc
14.3.12 Glpbio
14.3.13 Nanjing Xize Pharmaceutical Technology Co., Ltd
14.3.14 Shandong Haiwo Biotechnology Co., Ltd
14.3.15 J&K Scientific
14.3.16 Shanghai McLin Biochemical Technology Co., Ltd
14.3.17 Beijing Sjar Technology Development Co., Ltd.
14.3.18 Beijing Wokai Biotechnology Co., Ltd
14.3.19 Ningbo Zhenlei Chemical Co., Ltd.
14.3.20 Beijing Mreda Technology Co., Ltd
14.3.21 MedBio Pharmaceutical Technology Inc
14.3.22 Shanghai Dibai Biotechnology Co., Ltd
